A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors.

Trial Profile

A Cancer Research UK Phase I Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Aurora B Inhibitor GSK1070916A in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2014

At a glance

  • Drugs NMI 900 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 27 Apr 2013 Accrual to date is 102% according to United Kingdom Clinical Research Network.
    • 26 Apr 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network.
    • 24 Apr 2013 Accrual to date is 97% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top